BACKGROUND: Recurrent gastrointestinal bleeding is one of the most significant adverse events in patients with left ventricular assist devices (LVADs). METHODS: We enrolled LVAD patients who had received an intramuscular injection of 20 mg octreotide every 4 weeks as secondary prevention for recurrent gastrointestinal bleeding despite conventional medical therapies and repeated transfusions. The frequency of gastrointestinal bleeding and other associated clinical outcomes before and during octreotide therapy were compared. RESULTS: Thirty LVAD patients (66.4 ± 8.8 years old, 16 men [53%]) received octreotide therapy for 498.8 ± 356.0 days without any octreotide-associated adverse events. The frequency of gastrointestinal bleeding was decreased significantly during octreotide therapy (from 3.4 ± 3.1 to 0.7 ± 1.3 events/year; P < .001), accompanied by significant reductions in red blood cell and flesh frozen plasma transfusions, days in hospital, and need for endoscopic procedures (P < .05 for all). CONCLUSIONS: Octreotide therapy reduced the frequency of recurrent gastrointestinal bleeding and may be considered for secondary prevention.
BACKGROUND: Recurrent gastrointestinal bleeding is one of the most significant adverse events in patients with left ventricular assist devices (LVADs). METHODS: We enrolled LVADpatients who had received an intramuscular injection of 20 mg octreotide every 4 weeks as secondary prevention for recurrent gastrointestinal bleeding despite conventional medical therapies and repeated transfusions. The frequency of gastrointestinal bleeding and other associated clinical outcomes before and during octreotide therapy were compared. RESULTS: Thirty LVADpatients (66.4 ± 8.8 years old, 16 men [53%]) received octreotide therapy for 498.8 ± 356.0 days without any octreotide-associated adverse events. The frequency of gastrointestinal bleeding was decreased significantly during octreotide therapy (from 3.4 ± 3.1 to 0.7 ± 1.3 events/year; P < .001), accompanied by significant reductions in red blood cell and flesh frozen plasma transfusions, days in hospital, and need for endoscopic procedures (P < .05 for all). CONCLUSIONS:Octreotide therapy reduced the frequency of recurrent gastrointestinal bleeding and may be considered for secondary prevention.
Authors: Bart Meyns; Filip Rega; Joris Ector; Walter Droogne; Johan Vanhaecke; Jan Van Hemelrijck; Bartley Griffith; Robert Dowling; Mark Zucker; Daniel Burkhoff Journal: J Thorac Cardiovasc Surg Date: 2008-05-19 Impact factor: 5.209
Authors: David Feldman; Salpy V Pamboukian; Jeffrey J Teuteberg; Emma Birks; Katherine Lietz; Stephanie A Moore; Jeffrey A Morgan; Francisco Arabia; Mary E Bauman; Hoger W Buchholz; Mario Deng; Marc L Dickstein; Aly El-Banayosy; Tonya Elliot; Daniel J Goldstein; Kathleen L Grady; Kylie Jones; Katarzyna Hryniewicz; Ranjit John; Annemarie Kaan; Shimon Kusne; Matthias Loebe; M Patricia Massicotte; Nader Moazami; Paul Mohacsi; Martha Mooney; Thomas Nelson; Francis Pagani; William Perry; Evgenij V Potapov; J Eduardo Rame; Stuart D Russell; Erik N Sorensen; Benjamin Sun; Martin Strueber; Abeel A Mangi; Michael G Petty; Joseph Rogers Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Rajiv Malhotra; Keyur B Shah; Raveen Chawla; Sammy Pedram; Melissa C Smallfield; Anna G Priday; Christine T DeWilde; Donald F Brophy Journal: ASAIO J Date: 2017 May/Jun Impact factor: 2.872
Authors: Renzo Y Loyaga-Rendon; Taimoor Hashim; Jose A Tallaj; Deepak Acharya; William Holman; James Kirklin; Salpy V Pamboukian Journal: ASAIO J Date: 2015 Jan-Feb Impact factor: 2.872
Authors: Christopher T Sparrow; Michael E Nassif; David S Raymer; Eric Novak; Shane J LaRue; Joel D Schilling Journal: JACC Heart Fail Date: 2015-11-11 Impact factor: 12.035
Authors: Spencer D Lalonde; Ana C Alba; Alanna Rigobon; Heather J Ross; Diego H Delgado; Filio Billia; Michael McDonald; Robert J Cusimano; Terrence M Yau; Vivek Rao Journal: J Card Surg Date: 2013-07-11 Impact factor: 1.620
Authors: Anthony P Carnicelli; Anjali Thakkar; David J Deicicchi; Andrew C Storm; Jessica Rimsans; Jean M Connors; Mandeep R Mehra; John D Groarke; Michael M Givertz Journal: J Thromb Thrombolysis Date: 2019-04 Impact factor: 2.300
Authors: Davor Milicic; Binyamin Ben Avraham; Ovidiu Chioncel; Yaron D Barac; Eva Goncalvesova; Avishai Grupper; Johann Altenberger; Maria Frigeiro; Arsen Ristic; Nicolaas De Jonge; Steven Tsui; Jacob Lavee; Giuseppe Rosano; Marisa Generosa Crespo-Leiro; Andrew J S Coats; Petar Seferovic; Frank Ruschitzka; Marco Metra; Stefan Anker; Gerasimos Filippatos; Stamatis Adamopoulos; Miriam Abuhazira; Jeremy Elliston; Israel Gotsman; Righab Hamdan; Yoav Hammer; Tal Hasin; Lorrena Hill; Osnat Itzhaki Ben Zadok; Wilfried Mullens; Sanemn Nalbantgil; Massimo Francesco Piepoli; Piotr Ponikowski; Luciano Potena; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-14
Authors: Cecilia Berardi; Claudio A Bravo; Song Li; Maziar Khorsandi; Jeffrey E Keenan; Jonathan Auld; Sunny Rockom; Jennifer A Beckman; Claudius Mahr Journal: J Clin Med Date: 2022-04-05 Impact factor: 4.241
Authors: Tyler J Wilson; David A Baran; John M Herre; Chad M Cameron; Amin Yehya; Amanda I Ingemi Journal: ASAIO J Date: 2021-09-01 Impact factor: 3.826